Cantor Fitzgerald Issues Positive Outlook for REGN Earnings

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) - Analysts at Cantor Fitzgerald raised their FY2025 earnings per share (EPS) estimates for shares of Regeneron Pharmaceuticals in a report released on Wednesday, April 30th. Cantor Fitzgerald analyst C. Gould now anticipates that the biopharmaceutical company will post earnings per share of $26.88 for the year, up from their previous forecast of $26.38. Cantor Fitzgerald currently has a "Overweight" rating and a $695.00 price objective on the stock. The consensus estimate for Regeneron Pharmaceuticals' current full-year earnings is $35.92 per share.

A number of other research analysts have also recently commented on the stock. Robert W. Baird reduced their price target on shares of Regeneron Pharmaceuticals from $759.00 to $652.00 and set a "neutral" rating on the stock in a research report on Friday, April 25th. Bernstein Bank decreased their target price on shares of Regeneron Pharmaceuticals from $1,070.00 to $1,000.00 in a research report on Tuesday, February 4th. TD Cowen lowered their price objective on Regeneron Pharmaceuticals from $1,230.00 to $1,030.00 and set a "buy" rating for the company in a research report on Tuesday, February 4th. Truist Financial dropped their price objective on Regeneron Pharmaceuticals from $975.00 to $940.00 and set a "buy" rating for the company in a research note on Wednesday. Finally, UBS Group decreased their target price on shares of Regeneron Pharmaceuticals from $768.00 to $633.00 and set a "neutral" rating on the stock in a research note on Wednesday. One analyst has rated the stock with a sell rating, four have issued a hold rating, nineteen have assigned a buy rating and three have assigned a strong buy rating to the company. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus price target of $912.20.

Regeneron Pharmaceuticals Price Performance

REGN opened at $598.76 on Thursday. The stock has a 50-day moving average price of $631.31 and a 200-day moving average price of $717.21. The stock has a market capitalization of $65.46 billion, a P/E ratio of 15.64, a PEG ratio of 2.34 and a beta of 0.44. Regeneron Pharmaceuticals has a 12-month low of $525.99 and a 12-month high of $1,211.20. The company has a current ratio of 4.73, a quick ratio of 3.95 and a debt-to-equity ratio of 0.09.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last issued its quarterly earnings results on Tuesday, April 29th. The biopharmaceutical company reported $8.22 EPS for the quarter, missing analysts' consensus estimates of $8.83 by ($0.61). Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. The company had revenue of $3.03 billion during the quarter, compared to the consensus estimate of $3.40 billion. During the same period in the previous year, the company earned $9.55 EPS. Regeneron Pharmaceuticals's quarterly revenue was down 3.7% on a year-over-year basis.

Regeneron Pharmaceuticals Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, June 6th. Investors of record on Tuesday, May 20th will be issued a $0.88 dividend. The ex-dividend date of this dividend is Tuesday, May 20th. This represents a $3.52 dividend on an annualized basis and a yield of 0.59%. Regeneron Pharmaceuticals's dividend payout ratio is currently 2.30%.

Hedge Funds Weigh In On Regeneron Pharmaceuticals

A number of hedge funds have recently modified their holdings of the company. Willner & Heller LLC lifted its position in shares of Regeneron Pharmaceuticals by 3.9% in the fourth quarter. Willner & Heller LLC now owns 399 shares of the biopharmaceutical company's stock valued at $284,000 after acquiring an additional 15 shares in the last quarter. OLD Second National Bank of Aurora raised its position in Regeneron Pharmaceuticals by 0.5% during the fourth quarter. OLD Second National Bank of Aurora now owns 2,843 shares of the biopharmaceutical company's stock valued at $2,025,000 after purchasing an additional 15 shares during the period. Rakuten Securities Inc. boosted its holdings in shares of Regeneron Pharmaceuticals by 62.5% in the 4th quarter. Rakuten Securities Inc. now owns 39 shares of the biopharmaceutical company's stock worth $28,000 after purchasing an additional 15 shares during the period. TD Private Client Wealth LLC grew its position in Regeneron Pharmaceuticals by 9.6% in the 4th quarter. TD Private Client Wealth LLC now owns 171 shares of the biopharmaceutical company's stock valued at $122,000 after acquiring an additional 15 shares during the last quarter. Finally, Manchester Capital Management LLC increased its stake in Regeneron Pharmaceuticals by 12.6% in the 4th quarter. Manchester Capital Management LLC now owns 161 shares of the biopharmaceutical company's stock worth $115,000 after buying an additional 18 shares during the period. 83.31% of the stock is currently owned by institutional investors.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.